Bahlburg Henning, Noldus Joachim, Roghmann Florian
Klinik für Urologie und Neuro-Urologie, Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum, Hölkeskampring 40, 44625, Herne, Deutschland.
Urologie. 2025 Mar;64(3):288-294. doi: 10.1007/s00120-025-02522-8. Epub 2025 Feb 27.
Depending on the risk status, the treatment options for non-muscle-invasive bladder cancer (NMIBC) can include a bladder-preserving strategy with intravesical instillation treatment or early radical cystectomy. Established intravesical treatment options such as mitomycin C (MMC) or Bacillus Calmette-Guérin (BCG) are available to reduce the probability of progression and recurrence. This article classifies the intravesical treatment options in the therapeutic landscape of NMIBC and provides an overview of the indications and application regimens.
根据风险状况,非肌层浸润性膀胱癌(NMIBC)的治疗选择可包括采用膀胱内灌注治疗的保膀胱策略或早期根治性膀胱切除术。已有的膀胱内治疗选择,如丝裂霉素C(MMC)或卡介苗(BCG),可用于降低进展和复发的概率。本文对NMIBC治疗领域中的膀胱内治疗选择进行了分类,并概述了其适应证和应用方案。